Biofidelity raises $12mln for cancer diagnostics treatment

Biofidelity's Chief Executive Officer Dr Barnaby Balmforth speaks to Proactive London after raising $12 million to accelerate the launch of a disruptive cancer diagnostic technology. Dr Balmforth explains how the funds will be used to bring technology to the market, simplifying precision genetic testing to ensure many more cancer patients receive optimal diagnosis and therapy.

Read on Proactive